Trending Stocks Buzz: Energy Transfer Equity LP (NYSE:ETE), Gilead Sciences, Inc. (NASDAQ:GILD)

On Friday, Shares of Energy Transfer Equity LP (NYSE:ETE), added 4.17% and closed at $16.99 in the last trading session. The last trading range of the stock ranges between $16.05 and $17.37. The company’s Market capitalization is $18.53 Billion with the total Outstanding Shares of 1.05 billion. Energy Transfer Equity, L.P. (ETE) (“ETE” or the “Partnership”) recently stated financial results for the quarter ended September 30, 2016.

ETE’s net income attributable to partners was $209 million for the three months ended September 30, 2016 contrast to $293 million for the three months ended September 30, 2015. Distributable Cash Flow, as adjusted, for the three months ended September 30, 2016 was $281 million contrast to $325 million for the three months ended September 30, 2015. The decreases in net income attributable to partners and Distributable Cash Flow, as adjusted, were mainly driven by an $85 million reduction in incentive distributions from ETP. As formerly stated, ETE has agreed to a reduction in incentive distributions from ETP in the aggregate amount of $720 million over a period of seven quarters, starting the quarter ended June 30, 2016.

The Partnership’s recent key accomplishments and other developments include the following:

In October 2016, ETE declared a $0.285 distribution per ETE common unit for the quarter ended September 30, 2016, or $1.14 per unit on an annualized basis.

As of September 30, 2016, ETE’s $1.5 billion revolving credit facility had $885 million of outstanding borrowings and its leverage ratio, as defined by the credit agreement, was 3.08x.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $4.00 and reached to max level of $20.49. The EPS of company is strolling at 1.01.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD), dropped -1.80% and closed at $76.44 in the last trading session. The last trading range of the stock ranges between $75.29 and $77.51. The company’s Market capitalization is $98.87 Billion with the total Outstanding Shares of 1.32 billion. Gilead Sciences, Inc. (GILD) recently declared that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Vemlidy® (tenofovir alafenamide, TAF) 25 mg, an investigational, once-daily tablet for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (≥ 12 years and ≥ 35 kg body weight). The data included in the application support the use of TAF in treatment-naïve and treatment-practiced adults and adolescents with HBeAg-negative and HBeAg-positive HBV infection.

TAF is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at one-tenth the dose of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 245 mg. Data show that because TAF has greater plasma stability and more efficiently delivers tenofovir to hepatocytes contrast to TDF, it can be given at a lower dose, resulting in less tenofovir in the bloodstream. As a result, TAF improved certain renal and bone laboratory safety parameters contrast to TDF in clinical trials.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $71.39 and reached to max level of $108.63. The EPS of company is strolling at 10.78.

Leave a Reply

Your email address will not be published. Required fields are marked *